HIP-HIP-HOPE-3! Expanded role for statin therapy for primary prevention

September 15, 2016

The HOPE-3 trial sought to determine if blood pressure (BP) and cholesterol-lowering therapies are effective and safe as primary prevention strategies in intermediate risk patients. The American College of Cardiology and American Heart Association (ACC/AHA) guidelines support a risk-based approach to statin use but in intermediate risk patients the tradeoffs between benefit and risk were deemed “less clear.”  Do the results of HOPE-3 trial provide enough evidence to support routinely treating intermediate risk patients?

00:0000:00

PCSK9 Inhibitors: Blockbusters or Bust?

September 5, 2015

Two new mAbs, alirocumab and evolocumab, have been approved to treat elevated cholesterol when added to maximally tolerated statin therapy in patients with familial hypercholesterolemia or history of atherosclerotic cardiovascular disease (ASCVD). This new class of drugs, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, is considered to be the biggest breakthrough in cholesterol treatment since statins were approved 3 decades ago. But are they worth it?

00:0000:00

CVD Risk Scores - Are They Accurate?

July 28, 2015

How well do cardiovascular disease risk calculators really perform?  Do they over or underestimate risk?  Should we rely on them to make treatment decisions?

00:0000:00

Potential Uses of Niacin: Flushing Out The Results of HPS2-THRIVE

February 16, 2015

Guidelines promote the use of statins as first line therapy to prevent atherosclerotic cardiovascular disease events. Does adding niacin to statin treatment reduce residual risk?

00:0000:00